Diagnosis, misdiagnosis and management of hyperprolactinemia

Expert Review of Endocrinology and Metabolism

Volumn 1, Issue 1, 2006, Pages 123-132

  Healy, Marie Louise ^a   Smith, Thomas p P ^a   Mckenna, tj ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

dopamine agonists; hyperprolactinemia; infertility; macroprolactin; pituitary adenoma; prolactin

Indexed keywords

EID: 67649871382     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.1.1.123     Document Type: Article

References (50)

1. Franks S, Murray MA, Jequier AM, Steele SJ, Nabarro JD, Jacobs HS. Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin. Endocrinol. (Oxf.) 4, 597–607 (1975).
2. Moult PJ, Rees LH, Besser GM. Pulsatile gonadotrophin secretion in hyperprolactinemic amenorrhoea and the response to bromocriptine therapy. Clin. Endocrinol. (Oxf.) 16, 153–162 (1982).
3. Schlechte JA. Clinical practice. Prolactinoma. N. Engl J. Med. 349, 2035–2041 (2003).
4. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 5, 55–65 (2002).
5. Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002).
6. Schlechte JA. The macroprolactin problem. J. Clin. Endocrinol. Metab. 87, 5408–5409 (2002).
7. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin. Endocrinol. (Oxf.) 62, 633–643 (2005).
8. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003).
9. Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J. Clin. Endocrinol. Metab. 81, 2512–2514 (1996).
10. Suliman AM, Al-Saber F, Hayes F et al. Hyperprolactinaemia: analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital. Ir. Med. J. 93, 74–76 (2000).
11. Melmed S, Kleinberg D. Anterior Pituitary. In: Williams Textbook of Endocrinology. Williams R, Larsen P, Kronenburg H et al. (Eds). WB Saunders, CA, USA, 177–279 (2002).
12. Thorner MO, Vance ML, Laws ER, Horvath E, Kovacs K. The anterior pituitary. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, Kronenburg HM, Reed Larsen P (Eds). WB Saunders Company, PA, USA, 249–340 (1998).
13. Sam SM, Mark E. The pituitary mass: diagnosis and management. Rev. Endoc. Metab. Disord. 6, 55–62 (2005).
14. Rosato F, Garofalo P. Hyperprolactinemia: from diagnosis to treatment. Minerva Pediatr. 54, 547–552 (2002).
15. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with antiprolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994).
16. Smith TP, McKenna TJ. Prevalence of macroprolactinaemia in various hyperprolactinemic states. Irish J. Med. Sci. 167, 6 (1998).
17. Rogol AD, Rosen SW. Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J. Clin. Endocrinol. Metab. 38, 714–717 (1974).
18. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J. Clin. Endocrinol. Metab. 53, 863–866 (1981).
19. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. A normal ovulatory woman with hyperprolactinemia: presence of anti prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol. (Copenh.) 126, 497–500 (1992).
20. Leite V, Cosby H, Sobrinho LG, Fresnoza MA, Santos MA, Friesen HG. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 37, 365–372 (1992).
21. Fahie-Wilson MN, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann. Clin. Biochem. 42, 175–192 (2005).
22. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995).
23. Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to antiPRL autoantibodies. J. Clin. Endocrinol. Metab. 90, 3036–3044 (2005).
24. Pearson E, Paisley RB, Bower LM, Dearman GP, Fahie-Wilson MN, Alqhuist JAO. Macroprolactin in pregnancy, suckling and offspring. Endocrin. Abs. 1, 38 (2001).
25. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000).
26. Klibanski A. The effects of prolactin and oestrogen deficiency in amenorrhoic bone loss. J.Clin. Endocrinol. Metab. 67, 124–130 (1988).
27. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin. Reprod. Med. 20, 365–374 (2002).
28. Fahie-Wilson M. In hyperprolactinemia, testing for macroprolactin is essential. Clin. Chem. 49, 1434–1436 (2003).
29. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Effects of antiprolactin autoantibodies on serum prolactin measurements. Eur. J. Endocrinol. 130, 434–437 (1994).
30. Olukoga AO, Kane J. Screening for macroprolactinaemia. Ann. Clin. Biochem. 34, 701–703 (1997).
31. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005).
32. Fahie-Wilson MN. Polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 45, 436–437 (1999).
33. Gilberto J, Vieira H, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1789 (1998).
34. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002).
35. Aron DC, Howlett TA. Pituitary incidentalomas. Endocrinol. Metab. Clin. North Am. 29, 205–221 (2000).
36. Molitch ME. Pathological hyperprolactinaemia. Endocrinol. Metab. Clin. North Am. 22, 877–901 (1992).
37. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf.) 51, 119–126 (1999).
38. Molitch ME, Russell EJ. The pituitary ‘incidentaloma’. Ann. Intern. Med. 112, 925–931 (1990).
39. Webster J, Polli A et al. A comparison of cabergoline and bromocriptine n the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 331, 904–909 (1994).
40. Verhelst J, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518–2522 (1999).
41. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl J. Med. 349, 2023–2033 (2003).
42. Molitch ME. Pregnancy and a hyperprolactinemic woman. N.Engl. J. Med. 312, 1364 (1985).
43. Prager D, Braunstein G. Pituitary disorders during pregnancy. Endo. Metab. Clin. N. Am. 24, 1–4 (1995).
44. Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60, 698–705 (1985).
45. Biller BM, Molitch ME, Vance ML et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338–2343 (1996).
46. Fiad TM, McKenna TJ. Meningitis as a late complication of surgically and medically treated pituitary adenoma. Clin. Endocrinol. (Oxf.) 35, 419–422 (1991).
47. Olukoga AO, Dornan TL, Kane JW. Three cases of macroprolactinaemia. J. R. Soc. Med. 92, 342–344 (1999).
48. Cattaneo FA, Fahie-Wilson MN. Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report. J. Neurosurg. 95, 334–337 (2001).
49. Klee G. College of American Pathologists; Special Ligands Participants Summary Report. 10 (2004).
50. Sturgeon C, Ellis AR, Al-Sadie R, Logan M, Costa M. UK NEQAS for peptide hormones and related substances. Ann. Rev. 16–23 (2003).